Background

Inside the brain, there are proteins called c-Abl tyrosine kinases. Think of these like a malfunctioning switch. In Parkinson’s disease (PD), this switch gets stuck “on,” which triggers cellular damage and causes the disease to start and progress. An experimental drug called risvodetinib is designed to be brain-penetrant—meaning it can successfully cross the body’s natural protective barrier to get directly into the brain—turning that harmful switch off and offering a promising method for slowing down early Parkinson’s disease.

How the Study Was Done

The “201 Trial” was a Phase 2a study involving 137 people with early, untreated Parkinson’s disease.

• The Method: It was a “double-blind, placebo-controlled” study. This means some participants took a daily dose of the real drug (50 mg, 100 mg, or 200 mg) and others took a placebo (a harmless dummy pill). Neither the patients nor the doctors knew who got what until the end to ensure completely unbiased results.
• The Timeline: Participants took the pill once a day for 12 weeks, followed by 2 weeks of safety monitoring.

Study Results

Because this was an early-stage trial, the main goal was to see how the human body handles the drug rather than proving it cures the disease.

• Excellent Patient Completion: An impressive 95% of the participants successfully completed the entire 14-week study, showing that people didn’t find the treatment too difficult to stick with.
• Great Safety Profile: The drug met all of its safety goals. The number and type of side effects were practically the same for the people taking the real drug as it was for the people taking the fake placebo pill.
• Efficacy Measurements: While measurements of movement and daily life didn’t show a massive, statistically significant improvement yet, that is expected for a short, 12-week safety trial that wasn’t large enough to definitively measure symptom changes.

Conclusion

Risvodetinib proved to be safe, reliable, and well-tolerated by patients in the early stages of Parkinson’s. Because it successfully targets the specific brain proteins linked to the disease’s progression, the researchers concluded that the next step is to launch longer, larger studies to evaluate exactly how well it protects brain function over time.